Literature DB >> 31401291

A systematic review of sex-based differences in effectiveness and adverse effects of clozapine.

Susana Alberich1, Jessica Fernández-Sevillano2, Itxaso González-Ortega3, Judith Usall4, Marga Sáenz5, Eduardo González-Fraile6, Ana González-Pinto2.   

Abstract

Clozapine is one of the most widely used antipsychotics for treating psychiatric illnesses such as schizophrenia and bipolar disorder. This drug, however, is associated with adverse effects such as weight gain, metabolic syndrome, and blood dyscrasias. The manifestations of mental illness may differ between men and women. Yet, there is little evidence on the influence of sex on treatment response or the occurrence of AEs. To fill this gap of knowledge, we carried out a systematic review of the literature on sex differences in the effectiveness and adverse effects of clozapine. Scant evidence has been published on differences in effectiveness of clozapine between men and women. Indeed, to the best of our knowledge, this issue has only been addressed in a published study. Regarding adverse effects, males have been reported to be more likely to develop metabolic abnormalities such as cholesterol or triglycerides, hypertension, and cardiovascular risk, while females are at a higher risk for gaining weight, developing diabetes, and needing laxatives. Nevertheless, given the scarcity of sex-based studies on this drug, further studies are needed to explore sex-based differences, as the results obtained may be crucial to clinical practice and help improve the quality of life of patients.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adverse effects; Clozapine; Effectiveness; Sex-differences

Mesh:

Substances:

Year:  2019        PMID: 31401291     DOI: 10.1016/j.psychres.2019.112506

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

Review 1.  Course of Illness and Treatment Updates for Bipolar Disorder in the Perinatal Period.

Authors:  Melissa M Batt; Aviva K Olsavsky; Shaleah Dardar; Celeste St John-Larkin; Rachel L Johnson; Mary D Sammel
Journal:  Curr Psychiatry Rep       Date:  2022-02-15       Impact factor: 8.081

2.  Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects.

Authors:  Albert T Higgins-Chen; Marco P Boks; Christiaan H Vinkers; René S Kahn; Morgan E Levine
Journal:  Biol Psychiatry       Date:  2020-02-08       Impact factor: 13.382

Review 3.  The promises and pitfalls of sex difference research.

Authors:  Liisa A M Galea; Elena Choleris; Arianne Y K Albert; Margaret M McCarthy; Farida Sohrabji
Journal:  Front Neuroendocrinol       Date:  2019-12-16       Impact factor: 8.606

Review 4.  Targeting muscarinic receptors to treat schizophrenia.

Authors:  Daniel J Foster; Zoey K Bryant; P Jeffrey Conn
Journal:  Behav Brain Res       Date:  2021-02-26       Impact factor: 3.332

5.  Sex-Specific Associations Between Bipolar Disorder Pharmacological Maintenance Therapies and Inpatient Rehospitalizations: A 9-Year Swedish National Registry Study.

Authors:  Dragos C Ragazan; Jonas Eberhard; Jonas Berge
Journal:  Front Psychiatry       Date:  2020-11-12       Impact factor: 4.157

6.  Activation of the aryl hydrocarbon receptor by clozapine induces preadipocyte differentiation and contributes to endothelial dysfunction.

Authors:  K Fehsel; K Schwanke; B A Kappel; E Fahimi; E Meisenzahl-Lechner; C Esser; K Hemmrich; T Haarmann-Stemmann; G Kojda; C Lange-Asschenfeldt
Journal:  J Psychopharmacol       Date:  2022-01-03       Impact factor: 4.153

Review 7.  Antipsychotic medication for women with schizophrenia spectrum disorders.

Authors:  Bodyl A Brand; Yudith R A Haveman; Franciska de Beer; Janna N de Boer; Paola Dazzan; Iris E C Sommer
Journal:  Psychol Med       Date:  2021-11-12       Impact factor: 10.592

8.  Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort.

Authors:  J Vázquez-Bourgon; M Gómez-Revuelta; J Mayoral-van Son; J Labad; V Ortiz-García de la Foz; E Setién-Suero; R Ayesa-Arriola; D Tordesillas-Gutiérrez; M Juncal-Ruiz; B Crespo-Facorro
Journal:  Eur Psychiatry       Date:  2022-08-16       Impact factor: 7.156

9.  Isoform-specific roles for AKT in affective behavior, spatial memory, and extinction related to psychiatric disorders.

Authors:  Helen Wong; Josien Levenga; Lauren LaPlante; Bailey Keller; Andrew Cooper-Sansone; Curtis Borski; Ryan Milstead; Marissa Ehringer; Charles Hoeffer
Journal:  Elife       Date:  2020-12-16       Impact factor: 8.713

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.